|  | PRL-3 gene amplification |  | |||
---|---|---|---|---|---|---|
Variables | Total number | Negativity | Positivity | pvalue | ||
 |  | Number | (%) | Number | (%) |  |
PRL-3 expression | Â | Â | Â | Â | Â | 0.006 |
Negativity | 37 | 37 | (100) | 0 | (0) | Â |
Positivity | 40 | 32 | (80) | 8 | (20) | Â |
Age (years) | Â | Â | Â | Â | Â | 0.726 |
<60 | 34 | 30 | (88) | 4 | (12) | Â |
≥60 | 43 | 39 | (91) | 4 | (9) |  |
Gender | Â | Â | Â | Â | Â | 0.710 |
Male | 51 | 45 | (88) | 6 | (12) | Â |
Female | 26 | 24 | (92) | 2 | (8) | Â |
Lymphatic permeation | Â | Â | Â | Â | Â | 0.343 |
Absence | 15 | 15 | (100) | 0 | (0) | Â |
Presence | 62 | 54 | (87) | 8 | (13) | Â |
Vascular permeation | Â | Â | Â | Â | Â | 0.263 |
Absence | 25 | 24 | (96) | 1 | (4) | Â |
Presence | 52 | 45 | (87) | 7 | (13) | Â |
Differentiation | Â | Â | Â | Â | Â | 0.134 |
Well and moderate | 31 | 30 | (97) | 1 | (3) | Â |
Poor | 46 | 39 | (85) | 7 | (15) | Â |
Depth of invasion | Â | Â | Â | Â | Â | 0.006* |
T1 (m and sm) | 15 | 15 | (100) | 0 | (0) | Â |
T2 (mp and ss) | 35 | 33 | (94) | 2 | (6) | Â |
T3 (se) | 19 | 16 | (84) | 3 | (16) | Â |
T4 (si) | 8 | 5 | (63) | 3 | (38) | Â |
Lymph node metastasis | Â | Â | Â | Â | Â | 0.022 |
Absence | 29 | 29 | (100) | 0 | (0) | Â |
Presence | 48 | 40 | (83) | 8 | (17) | Â |
JCGC lymph node status†|  |  |  |  |  | 0.004* |
N0 | 29 | 29 | (100) | 0 | (0) | Â |
N1 | 21 | 20 | (95) | 1 | (5) | Â |
N2 | 20 | 14 | (70) | 6 | (30) | Â |
N3 and distant lymph nodes | 7 | 6 | (86) | 1 | (14) | Â |
UICC lymph node status‡ |  |  |  |  |  | 0.002* |
N0 | 29 | 29 | (100) | 0 | (0) | Â |
N1 | 18 | 17 | (94) | 1 | (6) | Â |
N2 | 16 | 13 | (81) | 3 | (19) | Â |
N3 and distant lymph nodes | 14 | 10 | (71) | 4 | (29) | Â |
JCGC stage | Â | Â | Â | Â | Â | 0.005* |
I (IA and IB) | 20 | 20 | (100) | 0 | (0) | Â |
II | 20 | 20 | (100) | 0 | (0) | Â |
III (IIIA and IIIB) | 19 | 15 | (79) | 4 | (21) | Â |
IV | 18 | 14 | (78) | 4 | (22) | Â |
UICC stage | Â | Â | Â | Â | Â | 0.003* |
I (IA and IB) | 21 | 21 | (100) | 0 | (0) | Â |
II | 20 | 20 | (100) | 0 | (0) | Â |
III (IIIA and IIIB) | 16 | 13 | (81) | 3 | (19) | Â |
IV | 20 | 15 | (75) | 5 | (25) | Â |